Phaseline

Companies › NOBO Medicine

NOBO Medicine: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Poseltinib (NB02)
Tyrosine-protein kinase BTK inhibitor
BTKPhase 2Primary CNS Lymphoma (PCNSL); Non Hodgkin Lymphoma (NHL)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07114367Poseltinib (NB02)Phase 1Non Hodgkin Lymphoma (NHL)OncologyDec 2026
NCT06737250Poseltinib (NB02)Phase 2Primary CNS Lymphoma (PCNSL)OncologyDec 2027

Targets

BTK (1)

Companies with the same targets

Sanofi BeOne Medicines Eli Lilly AstraZeneca Guangzhou Lupeng Pharmaceutical Company Zenas BioPharma (USA) Carna Biosciences Merck & Co. (MSD) Acerta Pharma Beijing InnoCare Pharma Tech

Companies built like this

TransThera Sciences (Nanjing) Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.